Quote:
Originally Posted by Riverwild
Efficacy rates by drug or what you get for your money.
Avonex 32%
Betaseron 34%
Copaxone 29%
Rebif 32%
Tysabri 67%
Gilenya 45%
|
That number for Tysabri is what Biogen tells us was the reduced "risk" for relapses/progression over placebo from their trials. Just recently, they quoted numbers from a two year study which showed a 37% reduced relapse/progression rate as compared to 7% for placebo, thus giving an approx 30% improvement. That put's it right in the CRAB category. While the cost for the drug is similar to the CRABs, the infusion charges on top of that make it by far the most expensive medication choice for MS patients.
Harry
04-19-2011, 08:27 AM
Reply With Quote
Similar Threads
Threaded Mode